Novocure's electric field therapy fails Phase 3 glioblastoma trial, not extending patient survival

Novocure announced on Thursday that its electric fields device, used together with standard chemoradiation, did not improve overall survival for patients with glioblastoma in a Phase 3 trial.

The study compared the combination therapy to chemoradiation alone and failed to meet its primary endpoint of extending patient lives, representing a setback for the company's plans to broaden the technology's use.

The negative outcome is likely to weigh on investor sentiment and may delay further development or regulatory steps as Novocure reevaluates its clinical strategy.